Table 1.
Summary of the included studies.
| Charles S. Fuchs (2021) | Hyun Cheol Chung, MD, PhD et al (2021) | Kohei Shitara et al (2018) | ||||
|---|---|---|---|---|---|---|
| Pembrolizumab (n = 294) | Paclitaxel (n = 276) | Pembrolizumab (n = 47) | Paclitaxel (n = 44) | Pembrolizumab (n = 294) | Paclitaxel (n = 276) | |
| Related to treatment | ||||||
| Age | 157 (53.4) | 233 (84.4) | 46 (98) | 43 (98) | 155 (53%) | 232 (84%) |
| Occurring in ≥ 10% in either group | ||||||
| Fatigue | 35 (11.9) | 64 (23.2) | 6 (13) | 5 (11) | 35 (12%) | 64 (23%) |
| Decreased appetite | 24 (8.2) | 43 (15.6) | 1 (2) | 11 (25) | 24 (8%) | 43 (16%) |
| Nausea | 17 (5.8) | 50 (18.1) | 2 (4) | 5 (11) | 17 (6%) | 50 (18%) |
| Diarrhea | 16 (5.4) | 38 (13.8) | 16 (5%) | 38 (14%) | ||
| Anemia | 10 (3.4) | 41 (14.9) | 1 (2) | 8 (18) | 10 (3%) | 39 (14%) |
| Alopecia | 1 (0.3) | 111 (40.2) | 1 (2) | 21 (48) | 1 (<1%) | 111 (40%) |
| Neuropathy, peripheral | 1 (0.3) | 40 (14.5) | 0 | 6 (14) | 1 (<1%) | 40 (14%) |
| Neutrophil count decreased | 0 | 35 (12.7) | 1 (2) | 17 (39) | 0 | 35 (13%) |
| Peripheral sensory neuropathy | 0 | 35 (12.7) | 0 | 5 (11) | 0 | 35 (13%) |
| Hypothyroidism | 24 (8.2) | 1 (0.4) | 5 (11) | 0 | 23 (8%) | 1 (<1%) |
| Hyperthyroidism | 12 (4.1) | 1 (0.4) | 12 (4%) | 1 (<1%) | ||
| Pneumonitis | 8 (2.7) | 0 | 8 (3%) | 0 | ||
| Infusion reactions | 5 (1.7) | 13 (4.7) | 5 (2%) | 13 (5%) | ||
| Hepatitis | 4 (1.4) | 0 | 4 (1%) | 0 | ||
| Hypophysitis | 4 (1.4) | 0 | 4 (1%) | 0 | ||
| Colitis | 3 (1.0) | 4 (1.4) | 3 (1%) | 4 (1%) | ||
| Severe skin reactions | 1 (0.3) | 1 (0.4) | 1 (<1%) | 1 (<1%) | ||
| Type 1 diabetes | 1 (0.3) | 0 | 1 (<1%) | 0 | ||
| Pancreatitis | 0 | 1 (0.4) | 0 | 1 (<1%) | ||
| Adrenal insufficiency | 1 (0.3) | 0 | ||||
| Treatment-related AE | 28 (60) | 42 (96) | ||||
| Grades 3–5 | 5 (11) | 28 (64) | ||||
| Led to discontinuation | 1 (2) | 6 (14) | ||||
| Led to death | 0 | 2 (5) | ||||
| White blood cell count decreased | 1 (2 | 13 (30) | ||||
| Aspartate aminotransferase | 0 | 5 (11) | ||||